


# EVOTEC AG

ISIN: DE0005664809 WKN: 566480 Asset Class: Stock

## Company

2024/05/10 17:43:00



Price

**9.52** EUR

Difference ▼ -1.30% (-0.13)



## Contact Details

EVOTEC SE

Tel: +49-40-56081-0

--

Fax:

+49-40-56081-222

Manfred Eigen Campus, Essener Bogen 7

Web:

<http://evotec.com>

22419 Hamburg

E-mail:

[info@evotec.com](mailto:info@evotec.com)

## Company Profile

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	903,162,000		1,073,671,000		1,100,940,000	
<b>Common stock capital</b>		177,186,000		176,953,000		176,608,000
<b>Fixed assets</b>	1,395,891,000		1,232,464,000		1,175,323,000	
<b>Equity capital of a company</b>		1,119,908,000		1,187,184,000		1,377,685,000
<b>Cash and cash equivalents</b>	510,909,000		415,155,000		699,326,000	
<b>Accrued liabilities</b>		16,062,000		16,427,000		18,021,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		464,573,000		337,706,000		324,516,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		714,572,000		781,245,000		574,062,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		156,676,000		207,113,000		34,943,000
<b>Total assets</b>	2,299,053,000	2,299,053,000	2,306,135,000	2,306,135,000	2,276,263,000	2,276,263,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	5,000	4,952	4,198
<b>Equity ratio</b>	48.71%	51.48%	60.52%
<b>Debt-equity ratio</b>	105.29%	94.25%	65.22%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	39.18%	11.72%	-4.75%

## Income statement

	2023	2022	2021
<b>Turnover</b>	781,426,000	751,448,000	618,034,000
<b>Net income</b>	-83,913,000	-175,655,000	215,510,000
<b>EBIT</b>	-101,365,000	-176,079,000	228,532,000
<b>Operating income before taxes</b>	-103,841,000	-180,893,000	221,550,000
<b>Cash Flow</b>	33,951,000	203,106,000	122,237,000
<b>Net interest income</b>	-2,476,000	-4,814,000	-6,982,000
<b>Research and development expenses</b>	112,529,000	76,642,000	72,200,000
<b>Income taxes</b>	-40,680,000	-21,202,000	-10,530,000
<b>Result from investments in subsidiaries, associates and other</b>	-20,752,000	-15,964,000	-16,570,000
<b>Revenues per employee</b>	156,285	151,746	147,221

## Board of Directors

Iris Löw-Friedrich	Chairman of Supervisory Board
Constanze Ulmer-Eilfort	Member of Supervisory Board
Elaine Sullivan	Member of Supervisory Board
Camilla Languille	Member of Supervisory Board
Roland Sackers	Member of Supervisory Board

## Members of Management Board

Mario Polywka	Chairman of Managing Board
Cord Dohrmann	Member of Executive Committee
Craig Johnstone	Member of Executive Committee
Matthias Evers	Member of Executive Committee
Laetitia Rouxel	Member of Executive Committee